Iqvia Holdings, Inc. · NYSE:IQV
Iqvia — Q2 2025 Earnings Presentation
13 slides from Iqvia's earnings presentation, August 2025
Slide 1: Indian Pharmaceutical Business Quarterly Insights – Q2 2025 (Apr-Jun)
Indian Pharmaceutical Business Quarterly Insights – Q2 2025(Apr-Jun) Report Release Date: August 2025 Dataset: TSA June 2025 © 2025. All rights reserved. IQVIA® is a registered trademark of IQVIA Inc. in the United States, the European Union, and various other countries.
Slide 2: Disclaimer
Disclaimer IQVIA is not an “authorised person” for the purposes of the Financial Services and Markets Act 2000 (“FSMA”) and does not provide investment advice or carry on any other regulated activity under Part II of the FSMA 2000 (Regulated Activities) Order 2001 The forecasts, projections, and rel
Slide 3: Agenda
AGENDA 1 Q2 2025 Performance analysis 2 H1 2025 Key highlights 3
Slide 4: Q2 2025 Performance analysis
AGENDA 1 Q2 2025 Performance analysis 2 H1 2025 Key highlights 4
Slide 5: Higher single digit growth for the quarter led by Chronic segment and MNCs
Higher single digit growth for the quarter led by Chronic segment and MNCs growing higher than Indian Co. IPM Value in ‘000 INR Cr 3% 7% 9% 56 60 59 57 61 53 Market Size & Gr • Q2 Mkt Size : 61K INR Cr • Q2 25 : 9% over Q2 24 • Q2 25 : 7% over Q1 25 Q1 24 Q2 24 Q3 24 Q4 24 Q1 25 Q2 25 Chronic / Acut
Slide 6: Higher growth from Respiratory acute therapy indicates seasonal impact
Higher growth from Respiratory acute therapy, esp Anti-Pyretics, Antihistamines & Cough preparations indicates seasonal impact. • Cephalosporins (44% contribution to AI therapy), 6% Gr. Macrolides and Anti-infectives Carbapenems each grew at 6%. High growth was seen from Tetra &comb / Q2 25 Gr over
Slide 7: Double digit growth seen across chronic therapies; GLP-1 high growth in Diabetes
Double digit growth seen across chronic therapies. With the advent of Wegovy & Mounjaro, GLP-1 sees high growth within the Diabetes TA. • Statins grew at 14% & Hypotensives dual Comb grew at 13%. They together Cardiac contribute ~39% of Cardiac therapy sales. Other Cardiac therapies viz.Hypotensive
Slide 8: West is the highest growing zone at 11%
West is the highest growing zone at 11% with Maharashtra and Gujarat reflecting double digit growth East North East North 25% 28% • East zone’s 8% Gr was driven • North is the leading zone in by West Bengal, Bihar, Kolkata, terms of contribution and Orissa and Jharkhand regions. growing at 8% over Q
Slide 9: Townclass analysis and Metros performance
Townclass analysis and Metros performance Qtr. Apr - Jun 25 : ₹ 61K Cr., 9% Gr • Metros indicated higher growths primarily led by Delhi (10%), Mumbai Extra Metros (18%), Hyderabad (14%), Bangalore (9%), Chennai (12%), Pune 35% share Urban 11% Gr (20%), Lucknow (13%) and Patna (14%) Metros 34% share
Slide 10: H1 2025 Key highlights
AGENDA 1 Q2 2025 Performance analysis 2 H1 2025 Key highlights 10
Slide 11: H1 2025 at a glance
H1 2025 at a glance Share of MNCs and Chronic TAs has gone up by 1% due to Mounjaro launch . Amongst top therapies, Cardiac and Neuro therapies reflected double digit growth 1 H1 2024 vis-à-vis H1 2025 2 Indian – MNCs split 3 Top Therapies Gr of H1 25 over H1 24 Value in INR Cr Values in INR Cr 7% G
Slide 12: Key highlights
Key highlights Cardiac, GI , CNS, Antineoplast, Urology Therapies reflected faster rate of growth than the market growth of 8% Sun, Abbott, Cipla, Intas, Torrent, DRL, Zydus, H1 2025 Companies IPCA, Glenmark, JB Pharma and FDC amongst the top 25 companies reflected faster rate of growth than the mar
Slide 13: Thank You
Thank You To learn more about Market drivers, current and emerging trends, current growth patterns, and market challenges contact us.